SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : 2021 Biotech Stock Picking Charity Contest
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Jack Hartmann1/1/2021 2:48:01 PM
1 Recommendation

Recommended By
Steve Lokness

  Read Replies (2) of 307
 
Here are my stocks - 10% to each

1) CERC Cerecor announces FDA acceptance of IND to study the use of CERC-007 to treat relapsed or refractory multiple myeloma; Initial data is expected in the first quarter of 2021
2) ORTX Orchard Therapeutics reports data from an ongoing proof-of-concept clinical trial evaluating the safety and efficacy of OTL-201 for the treatment of mucopolysaccharidosis type IIIA

3) THTX Theratechnologies announced new pre-clinical in vivo findings regarding its TH1902 for the treatment of several cancer types expressing the sortilin receptor

4) QURE uniQure presents initial data from its Phase III HOPE-B gene therapy trial of etranacogene dezaparvovec for the treatment of patients with severe and moderately severe hemophilia B

5) SESN Sesen Bio submits completed biologics license application to the FDA for Vicineum and Has requested priority review. Co announced submission of the completed Biologics License Application (BLA) to the FDA for Vicineum for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) on December 18, 2020.

6) BCLI Brainstorm Cell Therapeutics completed in the ongoing Phase 2 trial evaluating NurOwn as a treatment for progressive MS; Topline clinical trial results expected by the end of the first quarter 2021

7) ATHA Athira Pharma awarded research grant expected to total $15 mln over 3 years to support ACT-AD clinical trial in Alzheimer’s disease ACT-AD is a Phase 2 clinical study (NCT04491006) to evaluate ATH-1017 treatment in mild-to-moderate Alzheimer's disease. The study will use quantitative electroencephalogram (qEEG) and Event-Related-Potential (ERP P300) to assess the impact of treatment on certain brain wave signals, which are associated with learning, memory formation and higher cognitive functions. One of several secondary outcome measures of the study is the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11).

8) ARNA Arena Pharmaceuticals has achieved its targeted enrollment goal of 372 participants in the Phase 3 ELEVATE UC 52 trial evaluating the safety and efficacy of once-daily etrasimod in participants with moderately-to-severely active ulcerative colitis. Top-line data from the ELEVATE UC 12 and UC 52 trials are on track for Q1 of 2022.

9) LXRX Lexicon Pharma received Fast Track designation from the FDA for the development of LX9211 in diabetic peripheral neuropathic pain. Lexicon is currently enrolling patients with diabetic peripheral neuropathic pain in a Phase 2 proof-of-concept study of LX9211 and is preparing to initiate a second Phase 2 clinical trial of LX9211 in post-herpetic neuralgia.

10) PRVL Prevail Therapeutics announces first patient dosed in Phase 1/2 PROCLAIM clinical trial evaluating PR006 for the treatment of frontotemporal dementia patients with GRN Mutations (10.61) Co announced that the first patient has been dosed in the Phase 1/2 PROCLAIM clinical trial evaluating PR006, an investigational AAV9 gene therapy delivering the GRN gene, for the treatment of frontotemporal dementia patients with GRN mutations (FTD-GRN).



Charity is the usmwf.org
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News